This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Teva Pharmaceuticals: Pricing the 2016 Bond Offering -Teaching note
Schill, Michael J.; Yates, AdamTeaching Note DARDEN-F-2028TN-EFinanceTeaching note for the product F-2028Starting at €0.00
-
Teva Pharmaceuticals: Pricing the 2016 Bond Offering
Schill, Michael J.; Yates, AdamCase DARDEN-F-2028-EFinanceThis case examines the July 2016 decision by Israeli pharmaceutical Teva Pharmaceuticals Industries Limited (Teva) to raise USD19.5 billion in cash through a multicurrency bond offering to finance an acquisition that would firmly solidify Teva’s position as the largest generic pharmaceuticals manufacturer in the world. In light of a pending acquisition of Actavis, the generic drug manufacturing arm of Irish-US pharmaceutical Allergen Inc. (Allerg...Starting at €8.20